ArticleBrazilian dental journal2026
Chemoattractive potential of stem cells from apical papilla in peripheral blood monocytes: an in vitro study.
Article in Brazilian dental journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemokine (CC-motif) ligand 2 (CCL2) is the primary chemokine involved in monocyte migration from peripheral blood to tissues. These cells, in turn, will differentiate into macrophages and osteoclasts. Given that apical papilla stem cells (SCAP) are an important source of CCL2, this study aimed to investigate whether SCAP culture supernatant can recruit monocytes in vitro via CCL2. SCAP-conditioned medium (CM-SCAP) was obtained through primary culture after confirming the osteo/odontogenic differentiation potential of these cells. The supernatant was analyzed for CCL2 using an immunoenzymatic assay. Monocytes were isolated from human peripheral blood and positively selected using magnetic beads. CD 14+ cells were seeded into 5-μm pore transwell inserts placed in wells containing CM-SCAP. After 24 hours, the insert was removed, and the migrated cells were quantified using the Alamar Blue viability assay. Recombinant human CCL2 was used as a positive control, while the proliferation medium only was used as the negative control. CM-SCAP in the presence of a CCL2 neutralizer antibody was also tested. Statistical analysis was performed to assess group differences, considering data normality and a 5% significance level (p < 0.05). SCAP produced CCL2 in vitro, and none of the CM-SCAP dilutions affected monocyte viability. Wells containing CM-SCAP displayed a significant increase in cell migration compared to the control. This finding was abrogated by the CCL2 neutralizing antibody. Therefore, SCAP supernatant can induce monocyte migration in vitro through a CCL2-dependent mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.